IRIS UniCatt

Patrono, Carlo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.067
AS - Asia 2.927
EU - Europa 2.685
SA - Sud America 795
AF - Africa 76
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 5
Totale 9.581
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.993
SG - Singapore 1.283
CN - Cina 873
BR - Brasile 645
DE - Germania 617
SE - Svezia 495
IT - Italia 420
UA - Ucraina 329
IE - Irlanda 191
VN - Vietnam 171
GB - Regno Unito 157
FR - Francia 140
ID - Indonesia 134
IN - India 98
RU - Federazione Russa 87
FI - Finlandia 86
HK - Hong Kong 79
AR - Argentina 48
TR - Turchia 41
IQ - Iraq 34
CA - Canada 33
BD - Bangladesh 29
KR - Corea 26
JP - Giappone 22
NL - Olanda 22
AT - Austria 21
EC - Ecuador 20
ES - Italia 20
IR - Iran 20
MX - Messico 20
CL - Cile 19
ZA - Sudafrica 19
PE - Perù 18
BE - Belgio 17
AU - Australia 16
PK - Pakistan 16
PL - Polonia 16
SA - Arabia Saudita 14
CH - Svizzera 13
CO - Colombia 13
PH - Filippine 13
VE - Venezuela 12
EG - Egitto 11
CI - Costa d'Avorio 10
NZ - Nuova Zelanda 10
TH - Thailandia 10
PY - Paraguay 9
CZ - Repubblica Ceca 7
RO - Romania 7
UY - Uruguay 7
UZ - Uzbekistan 7
IL - Israele 6
KE - Kenya 6
MA - Marocco 6
TN - Tunisia 6
AZ - Azerbaigian 5
KZ - Kazakistan 5
MY - Malesia 5
AE - Emirati Arabi Uniti 4
BH - Bahrain 4
BO - Bolivia 4
DZ - Algeria 4
ET - Etiopia 4
JO - Giordania 4
KW - Kuwait 4
LT - Lituania 4
LV - Lettonia 4
NO - Norvegia 4
NP - Nepal 4
SI - Slovenia 4
AL - Albania 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
HN - Honduras 3
JM - Giamaica 3
MK - Macedonia 3
NI - Nicaragua 3
OM - Oman 3
SN - Senegal 3
SV - El Salvador 3
XK - ???statistics.table.value.countryCode.XK??? 3
A1 - Anonimo 2
BY - Bielorussia 2
CG - Congo 2
GE - Georgia 2
HU - Ungheria 2
LI - Liechtenstein 2
MD - Moldavia 2
PS - Palestinian Territory 2
PT - Portogallo 2
QA - Qatar 2
RS - Serbia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
CM - Camerun 1
DM - Dominica 1
GR - Grecia 1
GT - Guatemala 1
KH - Cambogia 1
Totale 9.568
Salva come PNG Salva come JPEG
Città #
Singapore 497
Chandler 408
Ashburn 329
Beijing 208
Jacksonville 186
Dublin 176
San Mateo 156
Nanjing 133
Jakarta 113
Hangzhou 102
Wilmington 94
Cattolica 87
Woodbridge 81
Boston 73
Hong Kong 72
Ann Arbor 70
Rome 69
Lawrence 63
Los Angeles 55
Ho Chi Minh City 54
Hefei 52
Milan 52
Moscow 51
Houston 50
Menlo Park 50
Redwood City 45
São Paulo 45
Hanoi 43
Nanchang 41
Munich 40
Dearborn 39
New York 38
Fairfield 36
Princeton 35
Dallas 33
Seattle 31
Chicago 30
Bremen 26
Mountain View 26
Redmond 26
Frankfurt am Main 25
Shenyang 25
Boardman 22
Buffalo 22
Hebei 22
Kunming 22
Lancaster 21
Izmir 20
Rio de Janeiro 20
Tokyo 18
Bareggio 17
Brussels 17
Tianjin 17
Belo Horizonte 16
Guangzhou 16
Kent 16
London 15
Santa Clara 15
Brasília 14
Curitiba 14
Guarulhos 14
Hyderabad 14
Seoul 13
Nuremberg 12
University Park 12
Augusta 11
Dhaka 11
Jiaxing 11
Leawood 11
Lima 11
Norwalk 11
Nürnberg 11
Abidjan 10
Detroit 10
Helsinki 10
Hounslow 10
Johannesburg 10
Philadelphia 10
Porto Alegre 10
Campinas 9
Denver 9
Vienna 9
Ankara 8
Baghdad 8
Brooklyn 8
Haiphong 8
Montreal 8
Pune 8
Shanghai 8
Sorocaba 8
Stockholm 8
Washington 8
Atlanta 7
Da Nang 7
Edinburgh 7
Lanzhou 7
Manchester 7
Montevideo 7
Paris 7
Quezon City 7
Totale 4.564
Salva come PNG Salva come JPEG
Nome #
Antiplatelet agents for the treatment and prevention of atherothrombosis 200
A randomized, double-blind trial of three aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia 177
The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes 176
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC) 174
Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors 157
In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus 155
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 154
In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes 151
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 145
Nutraceuticals in diabetes and metabolic syndrome. 142
Aspirin Continues to Attract Research and Debate, 115 Years After Its Synthesis 142
The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B(2) assay as an evaluation tool of different aspirin dosing regimens in the clinical setting 140
Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement 136
Increased thromboxane biosynthesis in essential thrombocythemia. 135
Low-dose aspirin for the prevention of atherothrombosis 131
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) 128
Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. 126
Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C →T polymorphism 126
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 121
Platelet activation and atherothrombosis 119
The coxibs, selective inhibitors of cyclooxygenase-2 114
Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis 113
Drug insight: aspirin resistance- fact or fashion 111
Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. 111
Aspirin: promise and resistance in the new millennium. 110
The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy 109
Determinants of the interindividual variability in response to antiplatelet drugs. 109
In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia 109
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 109
Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective 108
Non-steroidal anti-inflammatory drugs 107
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. 105
Antiplatelet therapy:aspirin for asymptomatic atherosclerosis? 103
Acute, periprocedural and longterm antithrombotic therapy in older adults: 2022 Update by the ESC Working Group on Thrombosis 103
Eicosanoid biosynthesis and metabolism in myeloproliferative disorders 100
Type 2 Diabetes, Obesity, and Aspirin Responsiveness* 100
Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells 100
Platelet progenitors: the hidden drug target 98
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials 98
Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective 98
Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. 97
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 97
Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) 96
Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment 94
Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials 94
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia 94
The future of antiplatelet therapy in cardiovascular disease 93
Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis 92
Fourth universal definition of myocardial infarction (2018) 92
Cigarette smoking knowledge and perceptions among students in four italian medical schools 90
Low-Dose Aspirin, Coxibs, and other NSAIDS: A clinical Mosaic Emerges. 88
Aspirin 86
The Key Contribution Of Platelet And Vascular Arachidonic Acid Metabolism To The Pathophysiology Of Atherothrombosis 85
Aspirin 84
In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance 83
Aspirin and Other COX-1 Inhibitors 83
Determinants of platelet activation in Alzheimer's disease. 82
Cyclooxygenase inhibitors: From pharmacology to clinical read-outs 78
Thromboxane biosynthesis and future events in diabetes: the ASCEND trial 77
The role of aspirin in cancer prevention 77
Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. 76
Nonsteroidal antiinflammatory drugs: past, present and future 76
Prostanoids, aspirin and related compounds 76
Measurement of Thromboxane Biosynthesis in Health and Disease 76
Effect of low-dose and standard-dose aspirin on PGE2 biosynthesis among individuals with colorectal adenomas: A randomized clinical trial 76
Interindividual Variability in response to aspirin and P2Y12 blockers in patients at high cardiovascular risk-the state of the evidence 74
Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety 74
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 74
On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens 74
Aspirin, 110 years later 73
Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. 71
Diabetes: Does aspirin increase the risk of major bleeds? 71
Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target 71
Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer 71
Mechanisms, consequences, and prevention of coronary graft failure 71
Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation 70
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials 67
Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets 66
The P2Y12 receptor: no active metabolite, no party 65
Aspirin at 120: Retiring, recombining, or repurposing? 65
Thromboxane biosynthesis in cancer patients and its inhibition by aspirin: a sub-study of the Add-Aspirin trial 64
Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. 64
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trial 63
Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither? 63
Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development 63
Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs 63
The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin 62
Platelet Cyclooxygenase Inhibition by Low-Dose Aspirin Is Not Reflected Consistently by Platelet Function Assays. Implications for Aspirin "Resistance" 62
Precision antiplatelet therapy 61
Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now 61
Antiplatelet Therapy 60
Nonsteroidal anti-inflammatory drugs and the heart 58
In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease 58
Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development 57
Knowledge about health effects of cigarette smoking and quitting among Italian university students: the importance of teaching nicotine dependence and treatment in the medical curriculum 57
Role of Clinical Pharmacology in the Development of Antiplatelet Drugs 56
Selective COX-2 inhibitors: where do we go from here? 54
Less Thromboxane, Longer Life 51
Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance" 49
Platelet activation in obese women: role of inflammation and oxidant stress 49
Totale 9.424
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.768
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.768
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021428 0 0 0 0 0 74 73 23 87 15 124 32
2021/2022787 73 74 12 51 62 21 25 128 38 25 112 166
2022/20231.367 209 189 123 164 146 160 37 93 145 23 51 27
2023/2024797 23 235 35 81 36 53 57 30 14 34 91 108
2024/20251.520 34 41 123 51 103 43 32 116 240 135 301 301
2025/20262.402 680 125 329 532 631 105 0 0 0 0 0 0
Totale 9.687